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ABSTRACT
The chromatin-associated enzyme PARP1 has pre-
viously been suggested to ADP-ribosylate histones,
but the specific ADP-ribose acceptor sites have
remained enigmatic. Here, we show that PARP1 co-
valently ADP-ribosylates the amino-terminal histone
tails of all core histones. Using biochemical tools
and novel electron transfer dissociation mass spec-
trometric protocols, we identify for the first time K13
of H2A, K30 of H2B, K27 and K37 of H3, as well as
K16 of H4 as ADP-ribose acceptor sites. Multiple
explicit water molecular dynamics simulations of
the H4 tail peptide into the catalytic cleft of PARP1
indicate that two stable intermolecular salt bridges
hold the peptide in an orientation that allows K16
ADP-ribosylation. Consistent with a functional
cross-talk between ADP-ribosylation and other
histone tail modifications, acetylation of H4K16
inhibits ADP-ribosylation by PARP1. Taken
together, our computational and experimental
results provide strong evidence that PARP1
modifies important regulatory lysines of the core
histone tails.
INTRODUCTION
Histone proteins form the nucleosome, which is the fun-
damental repeating unit of chromatin (1,2). Each nucleo-
some contains two heterodimers of the core histones H2A
and H2B, one tetramer of the core histones H3 and H4,
and 146 bp of DNA (3). Dynamic chromatin structures
are governed in part by post-translational modiﬁcations
of the histones, modiﬁcation of nucleotides, remodeling of
nucleosomes, and by non-coding RNAs or non-histone
DNA-binding proteins (4). The amino-terminal tails
of the core histone proteins protrude from the nucleo-
some. They appear to be unstructured and are believed
to participate in the formation of higher order chromatin
structures by mediating internucleosomal interactions
and to contact the linker DNA (3,5). A large number
of residues within the histones are modiﬁed by
post-translational modiﬁcations including acetylation,
phosphorylation, methylation, ubiquitination and ADP-
ribosylation, which occur in distinct patterns (6). Recent
work has provided compelling evidence that these modiﬁ-
cations inﬂuence the functional properties of chromatin.
Histones have long been known as substrates for
ADP-ribosylation in vivo (7). Histones isolated from rat
liver nuclei and HeLa cells incubated with radioactive
NAD+ revealed that the linker histone H1 and all core
histones, H2A, H2B, H3 and H4, are ADP-ribosylated,
although to a variable extent (8–12). An unresolved issue
regarding the mechanism of ADP-ribosylation of histones
is whether this modiﬁcation primarily occurs at the
globular histone domains or at their unstructured
amino-terminals tails. Moreover, unconﬁrmed ADP-
ribose acceptor amino acids have previously only been
proposed for H1 and H2B, but not for H2A, H3 and
H4 (11,13–15).
Poly(ADP-ribose) polymerase 1 (ARTD1/PARP1) is a
nuclear chromatin-associated multifunctional enzyme that
is present in most eukaryotes apart from yeast (16). The
enzyme is responsible for most of the cellular
poly(ADP-ribose) formation. Targets of PARP10s enzym-
atic activity include a variety of nuclear proteins, most
prominently PARP1 itself, as well as histone proteins
(17). Among the six PARP family members, PARP2 has
the highest similarity with PARP1 (43% sequence identity
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in the catalytic domain) (18). PARP2 displays similar
automodiﬁcation properties as PARP1 and may account
for the residual poly(ADP-ribose) synthesis observed in
PARP1 knockout mice.
Recently, we showed that individual lysine residues of
PARP1 and PARP2 function as acceptor sites for
auto-ADP-ribosylation and not, as previously assumed,
glutamic acid residues (19,20). Here, we report PARP1-
mediated ADP-ribosylation of the core histone proteins.
We found that PARP1, but not PARP2, ADP-ribosylates
core histone proteins at their amino-terminal tails. Mass
spectrometry of ADP-ribosylated histone peptides
revealed that the lysine residues K13 of H2A, K30 of
H2B, K27 and K37 of H3, as well as K16 of H4, are
speciﬁcally ADP-ribosylated by PARP1. Acetylation of
H4K16 or mutation of this residue to an alanine
abrogated ADP-ribosylation. Molecular dynamics (MD)
simulations of tetra- and octapeptide segments of the
amino terminal tail of H4 indicated that two positively
charged side chains at positions n and n+1 in the
histone sequence, which point in opposite directions, are
engaged in favorable electrostatic interactions with two
acidic PARP1 residues at the positions 988 and 756,
buried in the catalytic cleft and on a loop at the
entrance of the cleft, respectively. Taken together, our
results reveal that PARP1 speciﬁcally modiﬁes lysine
residues of the core histone tails, which are known to
control chromatin structure and function.
MATERIALS AND METHODS
Chemicals and antibodies
32P-NAD+was purchased from PerkinElmer. NAD+was
obtained from Sigma-Aldrich. Anti-PAR (LP-96-10)
antibody was from Becton Dickinson. Anti-PARP1
antibody was generated in this laboratory. PARP-
inhibitor DAM-TIQ-A was obtained from Alexis
Biochemicals, PJ34 was purchased from Enzo Life
Science, 3-amino-benzamide (3AB) was from Sigma-
Aldrich. Peptides were from PiProteomics. ProbondTM
nickel beads were from Invitrogen. Glutathione-
Sepharose 4B aﬃnity beads were from GE-healthcare.
Plasmids
The baculovirus expression vectors pQE-TriSystem
(Qiagen) and BacPak8 (Clontech) were used for the
expression of recombinant proteins in Sf21 cells as
described (21,22). pGEX-2T vectors (GE healthcare)
were used for the cloning and expression of GST-fusion
proteins. Full-length and truncated histone proteins were
expressed in pET3a or pET3d vectors, as described (3).
Sequencing of plasmids was performed by Microsynth
(Balgach, CH).
Cloning, expression and puriﬁcation of
recombinant proteins
Human PARP1 and PARP2 were cloned, expressed and
puriﬁed as described (19). Full-length histone proteins
were generated as described (3). GST-histone tail fusion
proteins were generated by PCR and cloned into
pGEX-2T vector. Truncated and mutated versions of
GST-fusion proteins were generated by cloning with
BstBI and EcoRI restriction sites. Primers for PCR and
direct cloning were obtained from Sigma-Aldrich and
Microsynth. pGEX-2T plasmids were transformed into
BL21(DE3) bacteria and expression was induced by
addition of 1mM IPTG into LB-medium for 3 h at
30C. After centrifugation and resuspension in
EBC-buﬀer (120mM NaCl, 50mM Tris–pH 8.0, 0.5%
NP-40, 5mM DTT, 1mM PMSF), bacteria were lysed
by the addition of lysozyme (0.5mg/ml) and the DNA
was sheared by a French Press. After centrifugation the
supernatant was taken and the proteins were bound to
GST-beads and washed extensively with EBC buﬀer.
The GST-beads with the bound GST-fusion proteins
were equilibrated with ADP-ribosylation buﬀer (50mM
Tris–HCl, pH 8.0, 4mM MgCl2, 250 mM DTT, 20mM
NaCl, 1 mg/ml protease inhibitors pepstatin, leupeptin
and bestatin) and after extensive washing eluted from
the GST-beads with 10mM reduced glutathione in
ADP-ribosylation buﬀer.
ADP-ribosylation assays
32P-NAD+ADP-ribosylation was performed as previously
described (19). Brieﬂy, 20 mg histone mix from calf thymus
(Roche) were incubated with 10 pmol PARP1 or PARP2
in a 25 ml reaction, containing 5 pmol annealed
EcoRI-linker DNA and 100 nM 32P-NAD+ in
ADP-ribosylation buﬀer (50mM Tris–HCl, pH 8.0,
4mM MgCl2, 250 mM DTT, 20mM NaCl, 1 mg/ml
protease inhibitors pepstatin, leupeptin and bestatin) for
10min at 30C. ADP-ribosylation of full-length or
truncated single histones was performed with 3 mg
full-length or truncated histone proteins and 10 pmol
PARP1 in a 25 ml reaction. ADP-ribosylation of
GST-histone tail fusion proteins was performed with
1.5mg puriﬁed fusion protein, together with 10 pmol of
PARP1. An amount of 5 pmol EcoRI-linker DNA was
always included into the reaction to activate PARP1 en-
zymatic activity. ADP-ribosylation assays with full-length
or truncated histones were resolved by a 10–20% acryl-
amide gradient SDS-gel of 15 cm length (Amersham).
Assays with GST-fusion proteins were resolved on
standard 12% acrylamide mini-gels (Hoefer).
Radiolabeled proteins were visualized by exposure to
X-ray ﬁlms or by quantiﬁcation through the phospho-
imager system (Molecular Dynamics).
For mass spectrometry, 22 nmol biotinylated H2A
(aa 3–23), H2B (aa 18–37), H3 (aa 23–42), H4 (aa 1–22)
or H4K16ac (aa 1–22) peptides were incubated with
10 pmol PARP1, 5 pmol annealed EcoRI-linker and 100
or 500 mM NAD+for 15min at 30C in ADP-ribosylation
buﬀer without protease inhibitors. The reaction was
stopped by the addition of 3AB to a ﬁnal concentration
of 20mM and subsequently 1 mg GST-ARH3 was added
to the reaction and further incubated for 1 h at 30C. The
samples were acetone precipitated and the pellet was
dissolved in distilled water.
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GST-pulldown
Glutathione–sepharose aﬃnity beads were incubated with
a bacterial extract of the GST-fusion protein expression in
EBC-buﬀer. After extensive washing, the GST-beads were
equilibrated with ADP-ribosylation buﬀer containing
50mM NaCl. After washing, 10 pmol puriﬁed PARP1
was added to the beads in a total volume of 300 ml
ADP-ribosylation buﬀer. The protein mixture was
incubated for 2 h at 4C on rolls to allow for protein–
protein interaction. The samples were washed again with
ADP-ribosylation buﬀer and resolved on standard SDS–
PAGE and subsequent western blotting with anti-PARP1
antibody.
Microvolume C-18 reversed phase puriﬁcation
An amount of 22 nmol H4-peptide (aa 1–22) was
incubated with 10 pmol PARP1, 5 pmol EcoRI-linker
DNA and 100 nM 32P-NAD+ in 25 ml ADP-ribosylation
buﬀer for 15min at 30C. The reaction was stopped by the
addition of 3AB to a ﬁnal concentration of 20mM. The
C18 reversed phase ZipTip (Millipore) was pre-wetted
with 100% methanol and equilibrated with 3% (v/v)
acetonitrile. The peptides were bound onto the column
and subsequently washed extensively with 3% (v/v) aceto-
nitrile. Bound peptides were eluted by 60% (v/v) acetoni-
trile directly into scintillation liquid. In the control
reaction, peptides were added after the addition of 3AB
to the reaction. Scintillation counts were measured and
normalized to the control reaction and the relative
increase in scintillation counts was calculated (cpm).
Mass spectrometry
Electron transfer dissociation (ETD) experiments were
performed on a hybrid LTQ Orbitrap XL ETD mass spec-
trometer (Thermo Scientiﬁc, Bremen, Germany) coupled
to an Eksigent nano LC system (Eksigent Technologies)
and the samples were analyzed by reversed-phase liquid
chromatography nanospray tandem mass spectrometry
(LC–MS/MS).
Peptides were resuspended in 3% ACN and 0.2%
formic acid, loaded from a cooled (10C) Spark Holland
autosampler (Emmen, Holland) and separated using
an ACN/water solvent system containing 0.2% formic
acid with a ﬂow rate of 200 nl/min. Separation of the
peptides was performed on a 10-cm long fused silica
column (75mm i.d.; BGB Analytik) in-house packed
with 3 mm, 200 A˚ pore size C18 resin (Michrom
BioResources, CA). Elution was achieved using a
gradient of 348% ACN in 35min, 4880% ACN in
4min and 80% ACN for 7min.
One scan cycle was comprised of a survey full scan MS
spectra from m/z 300 to 2000 acquired in the FT-Orbitrap
with a resolution of R=60000 at m/z 400, followed by up
to four sequential data-dependent ETD MS/MS scans
with detection of the ETD fragment ions in the linear
ion trap. AGC target values were 5 105 for full FTMS
scans, 104 for ion trap MSn scans. Anion target value was
106 and supplementary activation was employed to
enhance the fragmentation eﬃciency for doubly-charged
precursors and charge state dependent ETD time was
enabled. Data dependent decision tree was used in order
to control ETD dissociation based on charge state and m/
z. The ETD reaction time was set at 100ms and the iso-
lation width was m/z 2. For all experiments dynamic ex-
clusion was used with one repeat count, 30-s repeat
duration, and 10-s exclusion duration.
The instrument was calibrated externally according to
the manufacturer’s instructions. Orbitrap mass spectra
were acquired using internal lock mass calibration on
m/z 429.088735 and 445.120025. Spectra generated by
ETD were processed using Mascot Distiller 2.2 (Matrix
Science) and data was searched against a SwissProt
human database using Mascot 2.2.0 to ﬁnd best
matching sequences. Detailed spectra analysis was done
by manual evaluation.
Molecular dynamics
It is computationally prohibitive to dock the full-length
histone tails to PARP1. Therefore, only the relevant
tetra- and octapeptide segments of the histone tails
(abbreviated H-peptides hereafter) were taken into
account in the present study. A two-step procedure was
used to investigate the binding of the H-peptides to
PARP1 (PDB ID: 1A26). Preliminary binding modes of
the ﬂexible H-peptides into the rigid structure of the cata-
lytic domain of PARP1 were obtained by an in-house de-
veloped docking program, which uses a combination of
simulated annealing and genetic algorithm optimization
of position, orientation, and rotatable bonds of the
ligand (Zhao et al., unpublished). Explicit solvent MD
simulations of the H-peptide/PARP1 complexes were
then used to investigate the structural stability of the
poses obtained by docking. In both docking and MD
simulations, the N-terminus and C-terminus of the
H-peptides were capped by neutral groups (acetyl and
N-methlyamide, respectively) to take into account the
fact that they belong to a longer polypeptide chain. To
reproduce physiological pH conditions, the side chains of
aspartates and glutamates were negatively charged, those
of lysines and arginines were positively charged, while all
other residues were considered neutral. The MD simula-
tions were performed with the program NAMD (23) using
the all-atom CHARMM PARAM27 force ﬁeld (24) and
the TIP3P model of water (25). The H-peptide/PARP1
complexes were inserted into a cubic water box, with a
minimal distance of 12 A˚ between any solute atom and
the boundary of the box. Chloride and sodium ions were
added to neutralize the system and approximate a salt
concentration of 150mM. The water molecules
overlapping with the solute atoms or the ions were
removed, if the distance between the water oxygen and
any atom of the complex or any ion was smaller than
2.4 A˚. Periodic boundary conditions were applied to
avoid ﬁnite-size eﬀects. Electrostatic interactions were
calculated within a cutoﬀ of 12 A˚, while long-range elec-
trostatic eﬀects were taken into account by the particle
mesh Ewald summation method (26). Van der Waals
interactions were treated with the use of a switch
function starting at 10 A˚ and turning oﬀ at 12 A˚,
6352 Nucleic Acids Research, 2010, Vol. 38, No. 19
which is the default of the all-atom CHARMM force ﬁeld.
The temperature was kept constant at 300K by the
Langevin temperature control with a damping coeﬃcient
of 5 ps1, while the pressure was held constant at 1 atm by
applying a pressure piston. Before the production runs,
water molecules and ions were subjected to energy mini-
mization for 6000 steps, and a 1-ns equilibration with
harmonic constraints applied to the positions of the
C-alpha atoms. The covalent bonds involving hydrogen
atoms were constrained by means of the SHAKE algo-
rithm, and the dynamics were integrated with a time
step of 2 fs. Snapshots were saved every 2 ps for trajectory
analysis. Two MD runs with diﬀerent initial distribution
of velocities were carried out for each of the H4 peptides
AKRH and AKRHRKIL for a total simulation time of
150 ns for each peptide. Analysis of the trajectories was
carried out with the programs CHARMM (27) and
WORDOM (28).
RESULTS
PARP1 modiﬁes core histones
Recently, we reported the ADP-ribosylation of distinct
lysine residues of PARP1 and PARP2 in cis (19,20).
Since core histones were described earlier to be modiﬁed
by PARP1 in vitro and in vivo [(16) and Supplementary
Figure S1A and B], we set out to investigate which
residues of H2A, H2B, H3 and H4 would be modiﬁed
by PARP1, and possibly also by PARP2 in trans. First,
human PARP1 and PARP2 were expressed and puriﬁed
from insect cells using the baculovirus-system and were
subsequently incubated with full-length histones isolated
from calf thymus together with 100 nM radiolabeled
NAD+. Although automodiﬁcation of both PARP1 and
PARP2 was easily detectable, only PARP1 displayed de-
tectable trans-ADP-ribosylation of all four core histones,
indicating a clear diﬀerence in the substrate speciﬁcity
between PARP1 and PARP2 (Figure 1A). Similar experi-
ments with bacterially expressed and puriﬁed single
histone proteins revealed that, indeed, all four histones
are modiﬁed by PARP1 (Figure 1B).
PARP1 mono- and poly(ADP-ribosyl)ates amino-terminal
tails of core histone proteins covalently
Earlier reports suggested that histones are mainly
ADP-ribosylated at their amino-terminal tails (13,29). To
test whether PARP1-mediated ADP-ribosylation occurred
at the amino-terminal tails or at the globular histone folds,
we incubated the globular domains of histones H2B, H3
and H4 together with PARP1 and compared their
ADP-ribosylation to the full-length counterpart
(Supplementary Figure S2A). ADP-ribosylation of the
globular domains was reduced in comparison to full-length
histones, implying that indeed the amino-terminal tails are
required for modiﬁcation by PARP1. We then expressed
the diﬀerent histone tails as GST fusion proteins in bacteria
and incubated them with puriﬁed PARP1 and radiolabeled
NAD+. PARP1 was able to modify all four histone tails;
whereas comparable PARP2-mediated ADP-ribosylation
of histone tails was not detectable (Figure 1C and
Supplementary Figure S2B). This ﬁnding suggests that
the core histone tails are substrates speciﬁcally for
PARP1 but not for PARP2 in vitro. Previous reports
indicated that histones can interact with
poly(ADP-ribose) non-covalently via a PAR-binding
motif (30). Since the tested histone tails we analyzed did
not contain this motif, it is highly unlikely that the observed
labeling represented non-covalently attached PAR. To
exclude this notion experimentally, the histone tail fusion
proteins were added to the ADP-ribosylation reaction
either together with PARP1 or after the enzymatic
reaction had been stopped by addition of the
PARP-inhibitor 3AB. The addition of the histone tails
after the reaction did not result in their modiﬁcation
(Figure 1D, right panel), implying that the observed
ADP-ribosylation is a covalent modiﬁcation. To test
whether the observed modiﬁcation is an enzymatic
reaction, the reaction was repeated in presence of the
PARP-inhibitor PJ34. Increasing amounts of PJ34 abol-
ished trans-ADP-ribosylation of the H2B tail, as well as
automodiﬁcation of PARP1 (Figure 1E). Similar results
were obtained with a second PARP-inhibitor, DAM-
TIQ-A (Figure 1E). Taken together these results indicate
that PARP1 catalyzes the covalent ADP-ribosylation of
histone tails.
PARP1 is a mono- and a poly(ADP-ribosyl) transferase
(16). To determine whether the histone tails can be mono
and/or poly(ADP-ribosyl)ated by PARP1, we incubated
the histone tails with PARP1 in the presence of increasing
amounts of NAD+. Poly(ADP-ribosyl)ation was
determined by immunoblot analysis using an anti-PAR
antibody, which recognizes only polymers of ADP-ribose
(PAR). Both automodiﬁcation of PARP1 and
poly(ADP-ribosyl)ation of the histones were detected,
indicating that PARP1 can attach long polymers of
ADP-ribose onto histone tails (Figure 1F). Notably, the
length of poly(ADP-ribose) chains of the histones
increased proportionally to the amounts of NAD+, which
led to retarded migration of the modiﬁed proteins due to
an increased molecular weight (Figure 1F, ﬁlled asterisk).
ADP-ribosylation was earlier described to occur on glu-
tamates of H2B and H1 (11,15). These ﬁndings were never
directly attributed to PARP1 nor were they experimentally
conﬁrmed by mass spectrometry or amino-acid substitu-
tions. The PARP1-mediated ADP-ribosylation we
describe here occurred on the basic amino-terminal
histone tails, most of which do not contain glutamates
(Figure 2A). One exception is the tail of histone H2B
that contains one single glutamate. Mutation of this
residue to alanine did not aﬀect the levels of incorporated
ADP-ribose onto the H2B tail by PARP1 (Supplementary
Figure S2C), suggesting that glutamates are dispensable
and that additional residues can be eﬃciently
ADP-ribosylated by PARP1 in trans. Furthermore, when
we incubated poly-L-lysine or poly-L-glutamate with
puriﬁed PARP1 and measured incorporated ADP-ribose,
lysines but not glutamates were modiﬁed by PARP1
(Supplementary Figure S2D). These ﬁndings are consist-
ent with our previous reports (19,20) and provided add-
itional evidence that lysines are likely the primary target
sites for PARP1-mediated ADP-ribosylation.
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Identiﬁcation of ADP-ribose acceptor sites within
histone tails
As the amino-terminal histone tails are frequently targeted
by a variety of post-translational modiﬁcations with
important physiological functions (6), we aimed at
identifying the exact sites of PARP1-mediated ADP-
ribosylation. To this end, we ﬁrst generated a series of
histone tail deletion mutants to test in ADP-ribosylation
Figure 1. PARP1 covalently modiﬁes all four core histone tails. (A) PARP1 trans-ADP-ribosylates histones isolated from calf thymus. An amount of
10 pmol recombinant PARP1 or PARP2 were incubated for 15min (PARP1) or 30min (PARP2) at 30C with 5 pmol EcoRI-linker DNA, 100 nM
radiolabeled NAD+ and 20 mg extracted histones from calf thymus. The reaction was stopped by addition of SDS-lysis buﬀer and the proteins were
resolved on a 10–20% SDS–PAGE gradient gel. The gel was stained with Coomassie-R250 and incorporated 32P was visualized by autoradiography.
(B) Recombinant expressed and puriﬁed histones (3mg) were ADP-ribosylated by PARP1 as in Figure 1A. (C) An amount of 1.5 mg of each puriﬁed
GST-histone tail were used in PARP1 or PARP2 mediated trans-ADP-ribosylation reactions for 5min at 30C. (D) An amount of 1.5 mg of each
puriﬁed GST-histone tail were used in PARP1 mediated trans-ADP-ribosylation reactions for 5min at 30C. Histone tails were either included during
the reaction (pre) or added after the reaction had been stopped with a 100-fold excess of 3AB over radiolabeled NAD+ (post) to exclude
non-covalent interaction of the histone tails with PAR. (E) Trans-ADP-ribosylation of the H2B tail is inhibited by the PARP-inhibitors PJ34
(0.01–100mM) and DAM-TIQ-A (10 mM). (F) GST-histones were incubated with PARP1, EcoRI linker and increasing concentrations of NAD+
(0, 10, 100, 400mM) for 10min at 30C. Poly(ADP-ribose) formation was assessed through western blotting with anti-PAR (LP-96-10) antibody.
Unmodiﬁed GST-histone tails are marked by an empty asterisk, PARylated GST-histone tails are marked by a ﬁlled asterisk.
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assays (Figure 2A). Successive shortening of the histone
tails invariably resulted in a loss of PARP1-mediated
ADP-ribosylation and deﬁned for each histone the
region comprising putative ADP-ribose acceptor sites
(Figure 2B–E).
To directly identify the ADP-ribosylated amino acids
within the histone tails by mass spectrometry, we used
synthetic peptides covering the regions identiﬁed by our
deletion strategy. We incubated these peptides with
PARP1 in the presence of 100–500mM NAD+, stopped
the reactions by addition of 3AB and subsequently
treated the poly(ADP-ribosyl)ated peptides with
ADP-ribosylhydrolase 3 (ARH3). ARH3 is known to
possess PARG-like ADP-ribose glycohydrolase activity,
which hydrolyzes ester linkages between ADP-ribose
units (31). Since no negatively charged amino acids
(E or D), which would allow the formation of an ester
linkage, were present in the polypeptides (except for
H2B E35), we rationalized that treatment of the
modiﬁed polypeptides with ARH3 would leave the ﬁrst
ADP-ribose unit bound to the peptide. The ADP-
ribosylated peptides were acetone precipitated and
analyzed by liquid-chromatography coupled mass-
spectrometry. In the presence of PARP1 and NAD+,
the attachment of a single ADP-ribose unit resulted in
a mass shift of 541 Dalton (Figure 3A–D).
Fragmentation of ADP-ribosylated peptides with conven-
tional collision induced dissociation (CID) fragmentation
Figure 2. Conﬁning the regions of putative ADP-ribose acceptor sites. (A) Schematic representation of the deletion strategy for GST-histone tails to
identify the minimal ADP-ribosylated domain. (B–E) Trans-ADP-ribosylation of the indicated GST-histone deletion mutants by PARP1 with 100 nM
32P-NAD+.
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technique completely removed the ADP-ribose moiety
from the peptides, not allowing the identiﬁcation of
speciﬁc amino-acid acceptor sites (data not shown). In
contrast, analysis of the modiﬁed peptides by electron
transfer dissociation (ETD) resulted in an almost
complete fragmentation of the multiply charged histone
peptides, as indicated by the presence of c- and z-ions,
which represent N- or C-terminal fragment ions, respect-
ively (Figure 3A–D, Supplementary Figure S2E).
Fragmentation of the mono(ADP-ribosyl)ated H2A
peptide revealed speciﬁc ADP-ribosylation of K13, while
H2B was mainly ADP-ribosylated at K30 (Figure 3A
and B). H3 was ADP-ribosylated at K27 and K37
(Figure 3C and Supplementary Figure S2E). For H4,
mass spectrometric analysis identiﬁed K16 to be
ADP-ribosylated by PARP1 (Figure 3D). Control reac-
tions performed in the presence of 500 mM NAD+ but
without PARP1 or in the presence of 500mM
ADP-ribose and PARP1 did not result in speciﬁc
ADP-ribosylation (data not shown). The identiﬁed sites
of PARP1-mediated enzymatic ADP-ribosylation repre-
sent two known sites of frequent histone modiﬁcation
(H3K27 and H4K16) as well as novel modiﬁcation sites
(H2AK13, H2BK30 and H3K37). To verify the mass spec-
trometric data for one histone, the H4 tail was mutated at
K16 to alanine and tested for ADP-ribosylation by
PARP1. The mutated H4 tail showed severely reduced
ADP-ribosylation in comparison to the wild-type H4
tail (Figure 3E, ﬁlled asterisk). The reduction of
ADP-ribosylation was not due to a reduced interaction
of PARP1 with the mutated H4 tail, since wild-type and
mutated histone tail fusion proteins were able to interact
with PARP1 to comparable levels (Figure 3F).
Modeling of the histone H4 tail reveals that R17 is
critical for the interaction with the catalytic
domain of PARP1
In order to test computationally, whether the tail of H4
could enter the catalytic cleft of PARP1, automatic
docking followed by explicit solvent MD simulations
were performed with the crystal structure from chicken
PARP1 (PDB ID: 1A26), which uses the sequence num-
bering of human PARP1 (see ‘Materials and methods’
section). The MD simulations indicate that the H4
tetrapeptide segment AKRH (aa 15–18) binds in an
extended conformation to the catalytic domain of
PARP1 (Figure 4A and B). Two stable salt bridges are
observed in all MD runs: between H4K16 and PARP1
Glu988 in the catalytic cleft, and between H4R17 and
PARP1 Glu756 (Asp756 in human PARP1) on a loop at
the entrance of the cleft. These intermolecular salt bridges
lock H4 into the catalytic domain of PARP1 like two
stretched arms holding two points far away from each
other. In all MD runs, a single water molecule inserts
between the amino group of K16 and the carboxy group
of Glu988 in the ﬁrst 15 ns and remains between these two
charged groups until the end of the MD simulations of the
tetrapeptide (Supplementary Figure S3). This water
molecule occupies the same position as the water
molecule that is close to Glu988 in the X-ray structure
of PARP1 (water 37 in PDB code 1A26). There are two
additional side chains interactions: a stacking interaction
between the imidazole of H18 and the amide group of
Gln759 is almost always present in all MD runs, while
the hydrogen bond between the side chains of R19 and
Asn906 is not very stable. In contrast to the aforemen-
tioned intermolecular salt bridges and hydrogen bonds,
the K20 side chain is always exposed to solvent and very
ﬂexible. Furthermore, the backbone polar groups of the
histone do not seem to be involved in hydrogen bonds
with PARP1. Importantly, in all MD simulations both
the N-terminal and C-terminal methyl groups point
towards the solvent, which would allow the rest of
the H4 polypeptide chain to position itself close to the
surface of PARP1 without steric clashes. Moreover, the
MD runs with the H4 tetra- and octapeptide (aa 15–22)
converge towards a common extended structure of the
AKRH segment with the same side chain interactions.
The convergence of multiple MD simulations and the
agreement with the experimental results indicate that the
binding mode obtained by docking and explicit water MD
is reliable. To gain insight in the putative initiation step of
ADP-ribosylation, the 10 ns snapshot of the MD simula-
tion with the H4 tetrapeptide was used for docking NAD+
into the donor site as previously published (32,33). Before
docking, the nicotinamide was manually removed
(Figure 4C), which mimics the NADase activity of
PARP1 and creates a reactive C1-atom of the
ADP-ribose that is suggested to react with the substrate
amino acid (19,34,35). Interestingly, the C1-atom of the
ADP-ribose is only 3.7 A˚ away from the "-amino group of
H4K16 and 7.8 A˚ from the "-amino group of Lys903.
Moreover, the distance between the catalytic active
Glu988 carboxy group and the "-amino group of H4K16
is only 3.0 A˚, which would potentially allow covalent
ADP-ribosylation of H4K16 (Figure 4C).
To test experimentally whether an arginine close to
H4K16 is required for the interaction with PARP1, we
mutated R17 (H4R17A) and analyzed the association
with and the modiﬁcation by PARP1. GST-pulldown ex-
periments with recombinant PARP1 revealed that the
interaction between PARP1 and the mutated H4 tail
fusion protein was reduced (Figure 4D), as well as its
ADP-ribosylation by PARP1 (Figure 4E). In agreement
with the MD simulation and the mass spectrometry data,
an H4K16A/R17A double mutant was completely defect-
ive for PARP1-mediated ADP-ribosylation (Figure 4F).
Since H4R17 was suggested by molecular modeling to
interact with Asp756 of PARP1, we mutated Asp756
into a lysine (which is the corresponding amino acid
at this position in PARP2) and tested this mutant for
its ADP-ribosylation properties. The PARP1 mutant
exhibited no defect in auto(ADP-ribosyl)ation
(Supplementary Figure S2F), indicating that Asp756 is
not essential for automodiﬁcation. This is consistent
with the fact that also PARP2 is able to modify itself,
although it contains a lysine at the corresponding
position. Interestingly, however, the PARP1 mutant was
impaired in trans-ADP-ribosylation of full-length histones
(Figure 4G) and in the labeling of the H4 (1–22) peptide
(Supplementary Figure S1G), conﬁrming the MD-based
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Figure 3. Mass spectrometric analysis of ADP-ribosylated histone peptides. (A) Extracted ion chromatogram of the biotin tagged H2A (aa 3–23)
peptide incubated with 500mM NAD+ and PARP1. The precursor masses of unmodiﬁed H2A peptide (2395.34Da) and ADP-ribosylated H2A
peptide (2936.40Da) were plotted in a range of 10 ppm over time. ETD fragment spectrum of quintuply charged precursor ion of ADP-ribosylated
H2A peptide (638.51m/z) at K13, as indicated by the sequence plot. The spectrum shows next to the two major peaks of unfragmented charge
reduced precursor ions (M+5H)n+ an almost complete series of N-terminal and C-terminal fragment ions (c-ions, z-ions, respectively). (B) Extracted
ion chromatogram of the biotin tagged H2B (aa 18–37) peptide incubated with 500 mM NAD+ and PARP1 as in (A). ETD fragment spectrum
of ADP-ribosylated H2B peptide (797.89m/z) at K30, indicated by the sequence plot. (C) Extracted ion chromatogram of the biotin tagged H3
(aa 23–42) peptide incubated with PARP1 as in (A). ETD fragment spectrum of ADP-ribosylated H3 peptide (590.29m/z) at K27, indicated by the
sequence plot. (D) Extracted ion chromatogram of the biotin tagged H4 (aa 1–22) peptide incubated with 100 mM NAD+and PARP1. ETD fragment
spectrum of ADP-ribosylated H4 peptide (621.30m/z) at K16, as indicated by the sequence plot. (E) Trans-ADP-ribosylation of the GST-H4 histone
tail wild-type or K16A mutant by PARP1. (F) GST-pulldown of wild-type and mutated GST-histone H4 tails with recombinant PARP1.
The GST-histone tails are marked by an asterisk.
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Figure 4. Histone H4 interacts with PARP1 by salt bridges with acidic residues in the catalytic domain. (A) Representative snapshot of the binding
mode saved after 10 ns MD simulation of the H4 tetrapeptide AKRH. (B) Enlarged view of the catalytic cleft for the same snapshot as in (A). Amino
acids in close proximity of the H4 peptide are highlighted. PARP1 and the H4 tetrapeptide are shown in surface render and sticks, respectively. The
surface is colored according to atomic elements with carbon, oxygen and nitrogen in green, red, and blue, respectively. Carbon atoms of the H4
tetrapeptide are in cyan. (C) ADP-ribose was docked into the donor-site of PARP1 catalytic domain after 10 ns MD simulation of the H4
tetrapeptide. Amino acids in close proximity of the H4 peptide are highlighted. The orientation is rotated by about 180C with respect to (A,B).
(D) GST-pulldown of wild-type and mutated GST-histone H4 tail with recombinant PARP1 and subsequent western blot with anti-PARP1 antibody.
GST-histone tails are indicated by an asterisk. (E and F) Trans-ADP-ribosylation of wild-type and mutated GST-H4 tails with PARP1 and
radiolabeled NAD+. Coomassie stains of the input and autoradiographies are shown. (G) Trans-ADP-ribosylation of calf-thymus extracted
histones by PARP1 wild-type or PARP1 D756K mutant as in Figure 1A.
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prediction of the importance of this residue for stabiliza-
tion of the peptide in the catalytic cleft and subsequent
trans(ADP-ribosyl)ation of H4.
Acetylation of K16 inhibits ADP-ribosylation
of histone H4
Acetylation of H4K16 occurs frequently in eukaryotic
cells and has been correlated with chromatin
decompaction (6). If H4K16 was indeed an acceptor site
for PARP1-mediated ADP-ribosylation, acetylation at
that site should impair ADP-ribosylation. In order to
test this hypothesis, we employed an H4 peptide (aa 1–
22) chemically acetylated at K16. LC-coupled mass spec-
trometry of the H4K16ac peptide revealed that PARP1
was not any longer able to induce ADP-ribosylation of
the acetylated peptide above background (Figure 5A).
Consistent with this result, PARP1 mediated
ADP-ribosylation of both peptides (unmodiﬁed and
acetylated) with radiolabeled NAD+, followed by puriﬁ-
cation over a microvolume-C18 reversed phase column
and subsequent measurement of incorporated
radiolabeled NAD+, provided evidence that ADP-
ribosylation of the acetylated peptide was severely
reduced (Figure 5B). These results conﬁrm that H4K16
is modiﬁed by PARP1 and show that acetylation of K16
severely impairs ADP-ribosylation of the H4 peptide.
Together, our results led to the identiﬁcation of
ADP-ribose acceptor sites within the amino-terminal
tails of the four core histones (Figure 5C) and imply im-
portant cross-talks with other histone modiﬁcations such
as acetylation or methylation.
DISCUSSION
Here, we provide evidence that PARP1 covalently
modiﬁes the tails of all four core histones. We identiﬁed
H2AK13, H2BK30, H3K27, H3K37 and H4K16 as
speciﬁc target sites for PARP1-mediated ADP-
ribosylation. Our conclusions are based on several obser-
vations: (i) mass spectrometric analyses of
PARP1-mediated ADP-ribosylated peptides, (ii) loss of
function experiments by site directed mutagenesis of the
putative acceptor sites in recombinant histone tail fusion
proteins, (iii) cross-talk of acetylation and ADP-
ribosylation at the identiﬁed acceptor site in H4 and,
ﬁnally, (iv) prediction of the interaction between the
histone H4 tail and PARP1 by MD and subsequent con-
ﬁrmation with mutated proteins.
Nearly 20 years ago, ADP-ribose acceptor sites were
found in histones by biochemical approaches. Several
laboratories identiﬁed glutamic acid residues in histone
H1 and histone H2B to be modiﬁed when they incubated
chromatin from rat liver with radioactive NAD+ (11,13–
15). At that time, no other PARP family member had been
identiﬁed yet, and no knockout- or knockdown-system
was available. Thus, it is possible that PARP1, other
PARP-family members or even unrelated NAD+
consuming enzymes were responsible for the modiﬁcation
at the identiﬁed glutamates. In fact, we could show here by
mutational analyses, that E2 of H2B is dispensable for
PARP1-mediated ADP-ribosylation and that additional
amino-acid residues are acceptors for ADP-ribose
moieties. Consistent with this, we identify lysines in the
amino terminal histone tails and in particular lysine 13 of
H2A, lysine 30 of H2B, lysines 27 and 37 of histone H3, as
well as lysine 16 of histone H4 as target sites for enzymatic
ADP-ribosylation by PARP1, both by mass spectrometry
and amino-acid substitution. Therefore, we propose the
ADP-ribosylation of the "-amino group of lysines by
PARP1 as a new canonical histone tail modiﬁcation.
Remarkably, explicit solvent MD revealed that the
tetra- and octapeptides of H4 interact strongly with
speciﬁc amino-acid side chains of the catalytic cleft of
PARP1, suggesting that speciﬁc binding of a relatively
short segment of H4 is suﬃcient to allow
poly(ADP-ribosyl)ation of the histone tail. The positively
charged amino acid at the +1 position of the
ADP-ribosylated residue formed a salt bridge with
Glu756 of chicken PARP1, which corresponds to
Asp756 in human PARP1. In contrast, the corresponding
amino acid in PARP2 is a lysine at position 312. Although
the catalytic domains of PARP1 and PARP2 are highly
similar (18), the substrate speciﬁcity of those enzymes
might be regulated by subtle diﬀerences in the catalytic
cleft. This could explain why PARP2 does not modify
histones to a detectable extent at least in vitro (Figure
1A, C and Supplementary Figure S2B).
Application of novel mass spectrometry techniques
allowed us to identify distinct amino acids as acceptors
of ADP-ribose. We took advantage of the ETD technique
(36), which allows the fragmentation of highly charged
peptides, leaving most post-translational modiﬁcations
intact. Recent publications describe the technical basis
for the fragmentation of chemically ADP-ribosylated
peptides by electron capture dissociation (ECD) (37) and
the closely related ETD (38). It is noteworthy, that, in
contrast to other reports, we observed partial fragmenta-
tion of the ADP-ribose at the phosphodiester bond by
application of ETD, as revealed by the presence of a
m/z 348 ion. However, conventional CID mass spectrom-
etry of ADP-ribosylated H4 peptide did not reveal any
ADP-ribose acceptor sites, since the ADP-ribose was
cleaved oﬀ from the peptide during fragmentation. The
commonly used CID, instead of ETD, might thus explain
why numerous eﬀorts to identify ADP-ribosylated residues
failed in the past. Consequently, we would strongly recom-
mend ETD as standard technique to detect
ADP-ribosylated peptides. Of note, a previous study em-
ploying CID failed to detect ADP-ribosylated lysine
residues in the catalytic PARP1 mutant E988Q (39). In
summary, ETD can be expected to facilitate future inves-
tigations on ADP-ribosylated peptides, opening new
opportunities to screen for ADP-ribosylated residues in a
systems-biology setup.
Since poly(ADP-ribosyl)ated peptides cannot be
detected by MS and PARP1 mainly attaches
poly(ADP-ribose) to target proteins, we removed the
poly(ADP-ribose) with ARH3, which degrades
poly(ADP-ribose). However, this treatment was rather in-
eﬃcient (data not shown), which could partly explain the
observed low mono(ADP-ribosyl)ation of the histone
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Figure 5. ADP-ribosylation of the H4 peptide is impaired by H4K16 acetylation. (A) Elution proﬁle of biotinylated H4 peptide (aa 1–22) and
biotinylated H4K16ac peptide (aa 1–22) incubated with 100mM NAD+ for 15min without PARP1 (–PARP1) or in the presence of PARP1
(+PARP1) and subsequent ARH3 treatment. Acetone precipitated peptides were analyzed by LC–MS/MS using a C18 reversed-phase column
and subsequent detection by mass spectrometry. (B) Histone H4 (aa 1–22) and acetylated H4K16ac (1–22) peptides were ADP-ribosylated with
PARP1 for 15min at 30C with 100 nM 32P-NAD+. The peptides were puriﬁed by microvolume-C18 reversed phase columns, eluted into scintillation
liquid and counted for incorporated 32P. Relative increase of counts per minutes was calculated over background (peptides added after termination of
the reaction by 3AB). (C) Overview of the identiﬁed ADP-ribose acceptor sites within the amino-terminal core histone tails.
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peptides. Moreover, we cannot exclude that PARP1
modiﬁes additional residues, which were not identiﬁed
by these mass spectrometric analyses.
Our data provide strong evidence that PARP1-mediated
ADP-ribosylation of histones occurs as post-translational
modiﬁcation at distinct lysine residues within the
amino-terminal basic tails. From a chemical perspective,
modiﬁcation of a lysine residue by ADP-ribose results in
an unstable Schiﬀ base, which can undergo an Amadori
rearrangement to form a stable ketoamine (19,40). It will
be interesting to investigate whether histone lysine
ADP-ribosylation can be reversed by a previously
identiﬁed but still poorly characterized ADP-ribosyl
protein lyase (41). Since the attachment of ADP-ribose
not only neutralizes the positive charge of the amino-acid
side chain, but instead reverses it into a negative charge,
the functional consequences of lysine ADP-ribosylation
can be assumed to be even more drastic than those of
other modiﬁcations, such as acetylation. Therefore, the
possible eﬀects on chromatin architecture, histone
dynamics, histone degradation, and histone variant
incorporation may be dramatic. Possibly,
ADP-ribosylation of histones interferes with other
post-translational modiﬁcations of the histone tails. For
example, H3K27 is methylated by EZH2 (enhancer of
zeste homolog 2), which is in the polycomb group
complex that is involved in maintenance of the inactive
X-chromosome (42). Interestingly, PARP1 was
demonstrated to participate in the maintenance of
X-chromosome silencing as well (43). On the other
hand, the amino-terminal tail of histone H4 was shown
to be required for chromatin ﬁber formation, since the
positively charged stretch between K16 and K20 makes
internucleosomal contacts to two acidic patches on the
carboxy-terminal a-helices of histone H2A (44). In
addition to its function for chromatin topology, the
stretch between K16 and K20 is required for the inter-
action with various non-histone modulators. For
example, the ISWI-containing ATP dependent chromatin
remodeler ACF solely engages histone H4, but is repelled,
if H4K16 is acetylated (45,46). Furthermore, the chroma-
tin remodeler Alc1 was shown to require the K16 to K20
stretch of H4 for its activity (47). Interestingly, recent
reports provide evidence that the ATPase activity of
Alc1 is highly stimulated by binding to poly(ADP-
ribosyl)ated PARP1 (47,48). Whether ADP-ribosylated
H4 would activate Alc1, remains to be investigated.
Another intriguing possibility of how histone tail
ADP-ribosylation could aﬀect chromatin function is
implied by a recent study showing that macrodomain-
containing histone variants speciﬁcally bind to
poly(ADP-ribose) generated after DNA damage (49).
Using biochemical, crystallographic and state-of-the-art
imaging techniques, it was shown that macroH2A1.1
senses PARP1 activation and directly binds poly
(ADP-ribose) to cause a transient compaction of the chro-
matin. It will be interesting to investigate whether
macrodomains preferentially bind to automodiﬁed
PARP1 or also function as ‘readers’ of poly
(ADP-ribosyl)ated histone tails.
Taken together, the work presented here sheds new light
on a well known but neglected histone modiﬁcation and
builds the basis for future investigations exploring the
function of histone lysine ADP-ribosylation in chromatin
dynamics, transcription, DNA repair signaling and other
nuclear processes inﬂuenced by histone modiﬁcations.
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